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ABSTRACT
Objectives. We compared invasive pneumococcal disease (IPD) incidence 
by race/ethnicity and neighborhood poverty level and assessed their relative 
utility to describe disparities in IPD in 1998–1999 and again in 2007–2008, after 
introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). 
Methods. We conducted laboratory surveillance for pneumococcal isolates 
from sterile body sites and serotyped the isolates. Home address was geo-
coded to the census-tract level. Census-tract data on the percentage of people 
below poverty were grouped into three categories. The difference in the 
magnitude of incidence by race/ethnicity and by census-tract socioeconomic 
status (SES) (high poverty minus low poverty) was compared for 1998–1999 and 
2007–2008 for PCV7 and non-PCV7 serotypes.
Results. In 1998–1999, incidence difference (all per 100,000 population) for 
PCV7 serotypes for black people compared with white people was 14.3 and by 
poverty level was 13.9. The highest rate was among white people in high-
poverty tracts (77.3). By 2007–2008, there were only slight differences between 
rates for black and white people (0.7) and SES (1.4). In 1998–1999, the inci-
dence difference for non-PCV7 serotypes was 4.7 between black and white 
people and 6.0 by SES. By 2007–2008, the differences were 11.6 and 11.7, 
respectively. Among those living in the highest-poverty tracts, white people 
had the highest rate (42.9). 
Conclusions. In the absence of vaccine, IPD incidence is higher among people 
living in higher-poverty census tracts and among black people. Emerging sero-
types also follow this trend. Differences in neighborhood poverty levels reveal 
disparities in rates of IPD as large as those seen by race/ethnicity and could be 
used to routinely describe disparities and target prevention.
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Racial/ethnic disparities in pneumococcal disease 
occurrence in the United States have long been rec-
ognized, with black people having higher incidence 
of invasive pneumococcal disease (IPD) in all age 
groups compared with white people, and with variable 
incidence among other racial/ethnic groups, generally 
falling between the lower rates among white people 
and the higher rates among black people.1 These 
disparities were among those highlighted in Healthy 
People 2010, in which there was a specific objective 
to eliminate pneumococcal disease racial/ethnic 
disparities in the two age groups targeted by vaccine 
recommendations: adults 65 years of age for whom 
the 23-valent pneumococcal polysaccharide vaccine had 
long been recommended, and children 5 years of 
age for whom a new 7-valent pneumococcal conjugate 
vaccine (PCV7) was licensed in 2000.2 
Following the introduction in 2000 and subsequent 
widespread use of PCV7, there was a dramatic shift in 
the incidence and epidemiology of the most severe and 
easily monitored form of pneumococcal disease, IPD.3 
Not only did incidence decrease in the target group of 
children 5 years of age, but there also was evidence of 
community-level or “herd” immunity, with reductions in 
disease caused by the serotypes covered by PCV7 among 
all age groups.3,4 By 2004, racial/ethnic disparities 
had been greatly reduced and practically eliminated.1 
Shortly after, however, it became clear that several non-
vaccine serotypes of pneumococci, particularly serotype 
19A, were beginning to fill the niche vacated by those 
covered by PCV7. Disease caused by these non-vaccine 
serotypes began to steadily increase.5,6 Increases were 
noted particularly among people who were immuno-
suppressed and Alaska Native children.7,8 
The use of race/ethnicity as the sole social descrip-
tive variable for analysis to determine disparities has 
recently been called into question.9 For most diseases 
with racial/ethnic disparities, including pneumococcal 
disease, there does not appear to be a biological basis 
for incidence to be different, and for the most part, 
race/ethnicity is a surrogate for other social determi-
nants of health that are factors within and across racial/
ethnic groups such as poverty, crowding, low education 
level, and reduced health-care access. This finding has 
led to a call to begin to use other available measures 
of socioeconomic status (SES) to monitor disparities in 
addition to or in place of race/ethnicity.9 After more 
than five years of work to systematically identify the 
best available SES measure for disparities monitoring 
across a wide range of conditions of public health inter-
est, the Public Health Disparities Geocoding Project 
recommended use of a neighborhood measure, the 
percentage of people living below the federal poverty 
level (FPL) in their census tract.10 In 1999, the FPL for 
a family of four was $17,029.11 The choice of a census 
tract-level measure rather than an individual one was 
made for two major reasons: individual SES is usually 
not available in most routinely collected public health 
morbidity data, and neighborhood of residence is, in 
itself, a powerful independent factor in determining 
morbidity.10 
Connecticut has participated in the Emerging Infec-
tions Program network since it was created in 1995 and 
has contributed data to help elucidate racial/ethnic dis-
parities in IPD.12 Given the dynamics of pneumococcal 
disease incidence when examined by race/ethnicity, we 
sought to describe pre-PCV7 disparities by SES, using 
neighborhood poverty, as well as by race/ethnicity, and 
examine trends in reduction of PCV7 serotypes and 
emergence of replacement disease by these variables. 
To the extent that use of this SES measure described 
disparities that were as large as those described by race/
ethnicity, we felt it might be an appropriate measure 
to use routinely for future monitoring. 
MEthoDS 
The Connecticut Department of Public Health (CDPH) 
participates in Active Bacterial Core Surveillance as part 
of the Emerging Infections Program of Connecticut. 
As part of this surveillance project, active surveillance 
for IPD is conducted for the entire state. 
A case of IPD was defined by the isolation of Strepto-
coccus pneumoniae from a normally sterile body site of a 
Connecticut resident. Cases were reported to the CDPH 
by laboratories and clinicians. To ensure completeness 
of reporting, surveillance personnel performed routine 
audits of laboratory data of all 32 acute care hospital 
laboratories and two outpatient reference laboratories. 
Case data were collected through medical chart review 
for hospitalized patients and physician interview for 
outpatients. A standardized questionnaire was used 
to collect demographic, clinical syndrome, underlying 
risk factor, and outcome data. 
As part of laboratory reporting, pneumococcal 
isolates were sent to the Centers for Disease Control 
and Prevention’s Streptococcus Laboratory for confirma-
tion and serotyping. Pneumococcal serotypes included 
in PCV7 were defined as “vaccine serotypes.” This 
included serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. 
PCV7-related serotypes included all strains not in 
the vaccine but that cross-react with vaccine strains, 
including 6A, 9A, 9L, 9N, 18A, 18B, 18F, 19B, 19C, 
23A, and 23B. All other serotypes were characterized 
as “non-vaccine serotypes.” 
Records were geocoded to the census-tract level 
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using ArcGIS® version 9.1 software.13 Home address 
at the time of culture was used for geocoding. Cases 
with missing or invalid home addresses (post office 
box as address, incarcerated, or no match in U.S. 
Postal Service database) were excluded. Cases that had 
documented addresses that were unable to be matched 
during the geocoding process were matched to neigh-
boring addresses that fell within the same census tract. 
Census tract-level poverty data were determined for 
each case by matching the census tract of residence to 
2000 Census data. Cases were characterized as living 
in low-poverty (0% to 10% of residents living below 
FPL), medium-poverty (10% to 20% of residents 
living below FPL), or high-poverty (20% to 100% of 
residents living below FPL) census tracts. The high-
poverty category is consistent with the standard federal 
definition of a “poverty area.”
Incidence rates by year using 2000 Census data were 
calculated for total IPD, PCV7 serotypes, non-PCV7 
serotypes, and serotype 19A. For each pneumococcal 
category, incidence rates by year were also calculated 
for race/ethnicity and SES. To assess the relative impor-
tance of race/ethnicity and SES to describe dispari-
ties, the difference in the magnitude of the incidence 
rate by race/ethnicity and by SES (high poverty vs. 
low poverty) were calculated for the two years before 
the introduction of the vaccine (1998–1999) com-
pared with the two most recent post-vaccine-era years 
(2007–2008) for each of the pneumococcal categories 
defined previously. In addition, relative incidence was 
calculated using incidence among white people and 
in the lowest-poverty neighborhoods as the reference 
groups. To explore the effect of neighborhood poverty 
level on rates within racial/ethnic groups during the 
highest disparity periods, we examined rates of PCV7 
serotype-associated disease in 1998–1999 and rates of 
non-vaccine serotype disease in 2007–2008 by poverty 
level within racial/ethnic groups. We conducted all 
data analyses using SAS® version 9.2.14
RESultS
We identified 5,600 cases of IPD from 1998 to 2008; 
isolate serotype data were available for 5,023 (89.7%) 
cases. A total of 5,422 (96.8%) cases were able to be 
geocoded. Cases unable to be geocoded (n5178) 
were excluded due to invalid address (59.6%), post 
office box (25.8%), homeless (9.6%), missing address 
(3.9%), and incarcerated (1.1%). The percentage able 
to be geocoded to the census-tract level did not vary 
significantly by year (range: 93.2% to 98.8%).
The rates of IPD from 1998 to 2008 declined 
from a mean high of 21.9 per 100,000 population in 
1998–1999 to a mean low of 13.7 per 100,000 popula-
tion in 2005 and a mean of 14.7 per 100,000 popula-
tion in 2007–2008 (Figure 1). The overall decrease in 
IPD incidence was primarily driven by the decrease in 
incidence in PCV7 strains, which went from 12.8 per 
100,000 population in 1998–1999 to 0.9 per 100,000 
population in 2007–2008. During this time period, 
there was an increase in non-PCV7 strains from 6.8 per 
100,000 population in 1998–1999 to 12.1 per 100,000 
Figure 1. Invasive pneumococcal disease incidence, overall and by selected serotypes,  
by year: 1998–2008, Connecticut
PCV7 5 7-valent pneumococcal conjugate vaccine
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population in 2007–2008, and in serotype 19A from 
0.6 per 100,000 population in 1998–1999 to 2.6 per 
100,000 population in 2007–2008.
Table 1 shows the incidence of IPD for all serotypes 
by race/ethnicity and by SES in the pre-vaccine (1998–
1999) and post-vaccine (2007–2008) eras. Before the 
introduction of PCV7, rates among black people were 
2.1 times those among white people, with an incidence 
difference of 22.1 per 100,000 population. Rates among 
people living in the highest-poverty tracts showed a 
similar magnitude of disparity, being 2.4 times higher 
for those living in the poorest census tracts compared 
with the lowest-poverty tracts, with an incidence differ-
ence of 23.9 per 100,000 population. Seven and eight 
years after the introduction of PCV7, the incidence 
difference between black and white people dropped 
to 13.4 per 100,000 population, while the difference 
between high- and low-poverty tracts was of a similar 
magnitude, dropping to 14.3 per 100,000 population. 
Of interest, incidence of IPD among Hispanic people 
was not affected by the introduction of PCV7. 
Table 2 shows similar data for IPD attributable to 
PCV7 serotypes. In 1998–1999, there were marked 
disparities by race/ethnicity and neighborhood poverty 
level that were of a similar magnitude to each other. 
Incidence among black people was 2.2 times that of 
white people, with an incidence difference of 14.3 per 
100,000 population. The incidence among residents 
of high-poverty neighborhoods was 2.4 times that 
of residents in low-poverty neighborhoods, and the 
incidence difference was 13.9 per 100,000 population. 
Seven and eight years after the introduction of PCV7, 
these disparities were practically eliminated. The inci-
dence difference between black and white people was 
reduced to 0.7 per 100,000 population and the differ-
ence between higher- and lower-poverty neighborhoods 
was reduced to 1.4 per 100,000 population. 
Table 3 shows the emergence of non-vaccine sero-
types from 1998–1999 to 2007–2008. While there were 
initial disparities of comparable magnitude by race/
ethnicity and poverty level (incidence difference of 
4.7 per 100,000 population between black and white 
people, and 6.0 per 100,000 population between higher 
and lower neighborhood poverty levels), both disparities 
grew as incidence of IPD due to non-vaccine serotypes 
increased. By 2007–2008, the incidence difference 
between black and white people was 11.6 per 100,000 
population and by neighborhood poverty level was 11.7 
per 100,000 population. Of interest, while the incidence 
differences compared with white people increased over 
time for Hispanic people, too, the incidence differ-
ences did not increase for the mid-level poverty group 
compared with the lowest-level poverty group. 
We also examined whether disparities by race/eth-
nicity and neighborhood SES were heightened during 
the emergence of the most prominent non-vaccine 
Table 1. Invasive pneumococcal disease, all serotypes, incidence per 100,000, and changes over time,  
by race/ethnicity and poverty level: 1998–1999 to 2007–2008, Connecticut
Group
1998–1999 2007–2008
Number of 
cases Incidencea RRb
Incidence 
differencec
Number of 
cases Incidencea RRb
Incidence 
differencec
All 1,490 21.9 NA NA 999 14.7 NA NA
Race/ethnicity
 White 1,088 20.1 Ref. Ref. 690 12.8 Ref. Ref.
 Black 244 42.2 2.1 22.1 151 26.1 2.0 13.4
 Hispanic 132 21.4 1.1 1.3 137 22.2 1.8 9.4
Percentage of residents 
living in povertyd
 10% 853 16.9 Ref. Ref. 614 12.1 Ref. Ref.
 10% to 20% 259 29.1 1.7 12.2 140 15.7 1.3 3.6
 20% 266 40.7 2.4 23.9 173 26.5 2.2 14.3
aMean annual incidence per 100,000 people for the two-year period
bRelative incidence vs. reference group
cIncidence difference compared with reference group
dPercentage of people in census tract with income below the federal poverty level, 2000 Census
RR 5 rate ratio
NA 5 not applicable
Ref. 5 reference group
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serotype, 19A (Table 4). Although the number of 
cases was much lower, we observed a similar widening 
of incidence differences between black and Hispanic 
people vs. white people, and between people living in 
neighborhoods with high poverty levels vs. those living 
in neighborhoods with lower poverty levels. 
Table 2. Invasive pneumococcal disease, PCV7 serotypes, incidence per 100,000, and changes over time,  
by race/ethnicity and poverty level: 1998–1999 to 2007–2008, Connecticut
Group
1998–1999 2007–2008
Number of 
cases Incidencea RRb
Incidence 
differencec
Number of 
cases Incidencea RRb
Incidence 
differencec
All 871 12.8 NA NA 61 0.9 NA NA
Race/ethnicity
 White 623 11.5 Ref. Ref. 47 0.9 Ref. Ref.
 Black 149 25.8 2.2 14.3 9 1.6 1.8 0.7
 Hispanic 81 13.1 1.1 1.6 5 0.8 0.9 –0.1
Percentage of residents 
living in povertyd
 10% 496 9.8 Ref. Ref. 36 0.7 Ref. Ref.
 10% to 20% 154 17.3 1.8 7.5 9 1.0 1.4 0.3
 20% 155 23.7 2.4 13.9 14 2.1 3.0 1.4
aMean annual incidence per 100,000 people for the two-year period
bRelative incidence vs. reference group
cIncidence difference compared with reference group
dPercentage of people in census tract with income below the federal poverty level, 2000 Census
PCV7 5 7-valent pneumococcal conjugate vaccine
RR 5 rate ratio
NA 5 not applicable
Ref. 5 reference group
Table 3. Invasive pneumococcal disease, all non-vaccine serotypes, incidence per 100,000, and changes over time, 
by race/ethnicity and poverty level: 1998–1999 to 2007–2008, Connecticut
Group
1998–1999 2007–2008
Number of 
cases Incidencea RRb
Incidence 
differencec
Number of 
cases Incidencea RRb
Incidence 
differencec
All 465 6.8 NA NA 824 12.1 NA NA
Race/ethnicity
 White 355 6.6 Ref. Ref. 560 10.4 Ref. Ref.
 Black 65 11.3 1.7 4.7 127 22.0 2.1 11.6
 Hispanic 39 6.3 1.0 –0.3 118 19.1 1.8 8.8
Percentage of residents 
living in povertyd
 10% 270 5.3 Ref. Ref. 507 10.0 Ref. Ref.
 10% to 20% 80 9.0 1.7 3.6 115 12.9 1.3 2.9
 20% 74 11.3 2.1 6.0 142 21.8 2.2 11.7
aMean annual incidence per 100,000 people for the two-year period
bRelative incidence vs. reference group
cIncidence difference compared with reference group
dPercentage of people in census tract with income below the federal poverty level, 2000 Census
RR 5 rate ratio
NA 5 not applicable
Ref. 5 reference group
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Figure 2 shows the impact of neighborhood poverty 
level by racial/ethnic group for two distinct groups of 
IPD serotypes for which there were wide disparities by 
race/ethnicity and poverty level: PCV7 serotypes before 
PCV7 introduction and non-vaccine serotypes that have 
emerged since PCV7 introduction. For white people, 
there was a strong gradient by poverty for both groups, 
and white people living in high-poverty areas had the 
single highest rate of all people living in high-poverty 
areas. By contrast, trends for black and Hispanic people 
were not consistent and had no systematic association 
with poverty level. Among residents of the neighbor-
hoods with the least poverty, incidence of IPD was 
consistently higher among black and Hispanic people 
than among white people.
DISCuSSIon 
The reasons behind racial/ethnic, but particularly 
racial, disparities in the incidence of IPD—whether 
and to what extent they are social, economic, environ-
mental, medical (underlying disease), or genetic—have 
not been clear. Our study helps to shed light on fac-
tors that may contribute to racial/ethnic disparities by 
demonstrating that there is a strong socioeconomic 
component to them and that socioeconomic factors 
appear to play a role within individual racial/ethnic 
groups, particularly among white people. Before the 
introduction of PCV7, there were strong disparities in 
IPD incidence by neighborhood poverty level, as well 
as race/ethnicity, and these disparities were largely 
eliminated with high coverage levels of vaccine. When 
serotypes not covered by the vaccine emerged, they 
increased most among people living in poorer neigh-
borhoods, mirroring the disease distribution by SES 
before PCV7 introduction. Of particular note, white 
people showed the largest and most consistent gradi-
ent of IPD incidence by neighborhood SES, and white 
people living in the highest-poverty neighborhoods 
consistently had the highest rates of disease among 
people living in those neighborhoods. 
By contrast, neighborhood poverty levels had a 
much weaker, if any, association with IPD incidence 
among black and Hispanic people. The reason for this 
finding is not clear. One possible explanation is that 
the numbers of people in these groups in Connecticut 
are relatively small—particularly the number of cases 
among black and Hispanic people in the least impov-
erished neighborhoods—and the incidence is highly 
variable from year to year. However, it is also possible 
that there are other social factors operating in these 
groups. For example, social networks likely play a role 
in the probability of exposure to pneumococci, and it 
is possible that social networks among these groups 
in Connecticut are less hierarchical by SES than they 
are for the much larger white group. In addition, it is 
Table 4. Invasive pneumococcal disease, serotype 19A, incidence per 100,000, and changes over time,  
by race/ethnicity and poverty level: 1998–1999 to 2007–2008, Connecticut
Group
1998–1999 2007–2008
Number of 
cases Incidencea RRb
Incidence 
differencec
Number of 
cases Incidencea RRb
Incidence 
differencec
All 40 0.6 NA NA 179 2.6 NA NA
Race/ethnicity
 White 26 0.5 Ref. Ref. 112 2.1 Ref. Ref.
 Black 9 1.6 3.3 1.1 34 5.9 2.8 3.8
 Hispanic 4 0.7 1.4 0.2 27 4.4 2.1 2.3
Percentage of residents 
living in povertyd
 10% 23 0.5 Ref. Ref. 115 2.3 Ref. Ref.
 10% to 20% 10 1.1 2.5 0.6 25 2.8 1.2 0.5
 20% 5 0.8 1.7 0.3 31 4.8 2.1 2.5
aMean annual incidence per 100,000 people for the two-year period
bRelative incidence vs. reference group
cIncidence difference compared with reference group
dPercentage of people in census tract with income below the federal poverty level, 2000 Census
RR 5 rate ratio
NA 5 not applicable
Ref. 5 reference group
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possible that racial/ethnic segregation could result in a 
more socioeconomically heterogeneous group of black 
or Hispanic people living in each poverty-level neigh-
borhood. This could result in smaller neighborhood 
poverty differences in IPD incidence within racial/
ethnic minority groups than among white people. 
The main reason we decided to examine disparities 
by neighborhood SES was to find out whether dispari-
ties described by the SES measure recommended by 
the Public Health Disparities Geocoding Project, the 
percentage of people living below the FPL, described 
disparities that were as large as those measured by 
race/ethnicity.9 We identified disparities of a similar 
magnitude, whether using relative rates or incidence 
difference as the outcome measure. In addition, we 
observed large disparities within groups of white 
people categorized by this measure and found that 
white people living in poor census tracts had as high or 
higher rates of IPD as black and Hispanic people. Fur-
ther, we were able to describe a gradient of incidence 
by neighborhood poverty level, not just all-or-nothing 
extremes. Given these observations, we believe that 
future efforts to monitor disparities in IPD incidence 
should routinely include this measure and be used 
to target and monitor intervention and prevention 
measures, including education and vaccination, to 
the populations and geographic areas with the highest 
disease burden. 
Limitations
Our study had several notable limitations. Most impor-
tantly, the number of people and cases among black 
and Hispanic people in census tracts with lower poverty 
were small, reducing our ability to find differences 
within these racial/ethnic groups by neighborhood 
poverty level. It also prevented us from being able to 
meaningfully examine our data by age group. Second, 
we only attempted to use one neighborhood SES mea-
sure. One of the mechanisms by which poverty could 
affect IPD incidence is household crowding. Indoor 
crowding and time spent indoors likely underlie high 
levels of IPD and replacement disease in Alaska Native 
people8 and may also provide additional insight into 
trends in IPD in Connecticut. However, our purpose 
in using the measure we chose was to use the cur-
rently recommended standard measure for assessing 
disparities by SES. Third, our measure only looked 
at neighborhood SES. Personal SES, if known, likely 
would further contribute to the potential for dispari-
ties in disease incidence related to poverty. Finally, our 
denominators for all years were 2000 Census denomi-
nators, the only intercensal denominators available to 
use for census tract-level data. However, the main effect 
of using 2000 denominators for later years would be 
to slightly overestimate IPD incidence rates, assuming 
the population in each census-tract poverty category 
grew over time. 
Figure 2. Invasive pneumococcal disease incidence by neighborhood poverty level within racial/ethnic groups, all 
serotypes, 1998–1999, and non-vaccine serotypes, 2007–2008, Connecticut 
PCV7 5 7-valent pneumococcal conjugate vaccine
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ConCluSIonS
In the absence of vaccine, IPD incidence is higher 
among people living in higher-poverty census tracts 
and among black people. Emerging serotypes also fol-
low this trend. Differences in neighborhood poverty 
levels reveal disparities in rates of IPD as large as those 
seen by race/ethnicity and could be used to routinely 
describe disparities and target prevention efforts.
The authors thank the staff of the Centers for Disease Control 
and Prevention’s Streptococcus Laboratory for serotyping the 
invasive pneumococcal isolates.
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